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Cancer vaccine therapy is one of the most attractive therapies as a new treatment 
procedure for pancreatic adenocarcinoma. Recent technical advances have enabled the 
identification of cytotoxic T lymphocyte (CTL) epitopes in various tumor-associated 
antigens (TAAs). However, little is known about which TAA and its epitope are the 
most immunogenic and useful for a cancer vaccine for pancreatic adenocarcinoma. We 
examined the expression of 17 kinds of TAA in 9 pancreatic cancer cell lines and 12 
pancreatic cancer tissues. CTL responses to 23 epitopes derived from these TAAs were 
analyzed using enzyme-linked immunospot (ELISPOT), CTL, and tetramer assays in 41 
patients, and factors affecting the immune responses were investigated. All TAAs were 
frequently expressed in pancreatic adenocarcinoma cells, except for adenocarcinoma 
antigens recognized by T cells (ART)1, melanoma-associated antigen (MAGE)-A1, and 
MAGE-A3. Among the epitopes recognized by CTLs in more than two patients in the 
ELISPOT assay, 6 epitopes derived from 5 TAAs, namely, MAGE-A3, p53, human 
telomerase reverse transcriptase (hTERT), Wilms tumor (WT)-1, and vascular 
endothelial growth factor receptor (VEGFR)2, could induce specific CTLs that showed 
cytotoxicity against pancreatic cancer cell lines. The frequency of lymphocyte subsets 
correlated well with TAA-specific immune response. Overall survival was significantly 
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longer in patients with TAA-specific CTL responses than in those without. P53, hTERT, 
WT-1, and VEGFR2 were shown to be attractive targets for immunotherapy in patients 
with pancreatic adenocarcinoma and the induction of TAA-specific CTLs may improve 
the prognosis of these patients. 
 
 





Précis: P53, hTERT, WT-1, and VEGFR2 were the most suitable epitopes for cancer 
vaccine therapy in pancreatic adenocarcinoma. Outcomes were significantly better in 





Pancreatic adenocarcinoma is the fourth leading cause of cancer death worldwide 
[1]. Despite recent advances in diagnostic techniques, pancreatic adenocarcinoma is 
diagnosed at an advanced stage in most patients and, consequently, the overall 5-year 
survival rate is less than 5% [2]. Thus, the development of a new treatment option is 
needed to improve the prognosis of pancreatic cancer patients without toxicity. 
Immunotherapy is one of the most attractive therapies as a new treatment 
procedure for melanoma and other solid tumors [3]. Recent technical advances have 
enabled the identification of various tumor-associated antigens (TAAs) [4-21]; however, 
few of their epitopes are inducers of cytotoxic T lymphocyte (CTL) responses against 
tumors [22]. Several kinds of epitope have also been identified in patients with 
pancreatic adenocarcinoma [23,24]. However, previous studies focused on the 
identification and evaluation of a particular antigen, and different TAAs have not yet 
been compared simultaneously; therefore, little is known about which epitope is the 
most immunogenic and useful in eliciting clinical responses in pancreatic 
adenocarcinoma patients. 
In the present study, we compared CTL responses to various TAA-derived 
epitopes in identical patients with pancreatic adenocarcinomas and examined the factors 
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that affect immune responses. This approach provided information that is useful for 
selecting immunogenic TAAs and suitable patients, and developing a new 






Materials and Methods 
Patients and clinical information 
In this study, we examined 41 HLA-A24 positive patients with pancreatic 
adenocarcinoma and 14 healthy volunteers who were HLA-A24 positive but did not 
have any cancers, as negative controls. Fine-needle biopsy, a surgical specimen, or 
autopsy was used for the pathological diagnosis of pancreatic adenocarcinoma in 18 
patients. Diagnosis of the remaining 23 patients was achieved using the radiological 
findings of computed tomography and/or magnetic resonance imaging. We investigated 
patient background, treatment procedures, and outcomes.  
Clinical information was obtained from the medical records of patients. We 
evaluated the tumor stage using TNM staging of the Union Internationale Contre Le 
Cancer (UICC) system (7th version) (UICC stage). The frequency of lymphocyte 
subsets was calculated by dividing the absolute lymphocyte count by the absolute 
leukocyte count. HLA typing of peripheral blood mononuclear cells (PBMCs) from 
patients and healthy volunteers was performed by the reverse sequence-specific 
oligonucleotide with polymerase chain reaction (PCR-RSSO). This study was approved 
by the Ethics Committees of Kanazawa University (No. 1237) and Kanazawa Medical 
Center (No. 17), and all patients gave written informed consent to participate in 
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accordance with the Helsinki Declaration. 
 
Synthetic peptides and preparation of PBMCs 
The 23 epitopes derived from 17 different TAAs used in the present study are 
listed in Table 1. We selected epitopes that had previously been identified as 
HLA-A24-restricted and suggested to have immunogenicity in various cancers not 
restricted to pancreatic cancer [4-21]. Epitopes derived from the HIV envelope protein 
(HIV env584) [25] and cytomegalovirus (CMV) pp65 (CMVpp65328) [26] were also used 
to assess T-cell responses. Peptides were synthesized at Mimotope (Melbourne, 
Australia), Sumitomo Pharmaceuticals (Osaka, Japan), COSMO BIO Co. (Tokyo, 
Japan), and Scrum Inc. (Tokyo, Japan).  Purities were determined to be >80% by 
analytical high-performance liquid chromatography (HPLC). PBMCs were separated as 
described below; heparinized venous blood was diluted in phosphate-buffered saline 
(PBS) and loaded on Ficoll-Histopaque (Sigma, St. Louis, MO) in 50 ml tubes. After 
centrifugation at 2000 rpm for 20 min at room temperature, PBMCs were harvested 
from the interphase, resuspended in PBS, centrifuged at 1400 rpm for 10 min, and 
finally resuspended in complete culture medium consisting of RPMI (GibcoBRL, Grand 
Island, NY), 10% heat-inactivated FCS (Gibco BRL), 100 U/ml penicillin, and 100 
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μg/ml streptomycin (Gibco BRL). 
 
Cell lines 
The HLA-A*2402 gene-transfected C1R cell line (C1R-A24) was cultured in 
RPMI 1640 medium containing 10% FCS and 500 μg/ml hygromycin B (Sigma, St. 
Louis, MO), and K562 was cultured in RPMI 1640 medium containing 10% FCS [27]. 
MiaPaca2, AsPC1, BxPC3, Panc-1, CAPAN1, and CAPAN2 were purchased from the 
American Type Culture Collection (VA, USA). YPK-1 and YPK-2 were kind gifts from 
Prof. Oka and Dr. Yoshimura (Yamaguchi University Graduate School of Medicine, 
Yamaguchi, Japan). PK-1 was provided by the RIKEN BRC through the National 
Bio-Resource Project of MEXT, Japan. Human pancreatic cancer cell lines were 
cultured in DMEM (GibcoBRL) or RPMI 1640 medium containing 10% fetal calf 
serum (FCS). All media contained 100 U/mL penicillin and 100 μg/mL streptomycin. 
 
RNA preparation and real-time PCR 
The expression of TAA messenger RNA (mRNA) in human pancreatic cancer cell 
lines and pancreatic adenocarcinoma tissues was analyzed by real-time polymerase 
chain reaction (PCR). Cell lines were harvested, centrifuged, and washed with PBS and 
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total RNA was then isolated using Quick-Gene (Fuji Film, Tokyo). Total RNA from 
frozen pancreatic adenocarcinoma samples was isolated using a GenElute Mammalian 
Total RNA Miniprep Kit (Sigma-Aldrich) according to the manufacturer’s protocol. 
cDNA was synthesized from 150 ng of total RNA using a high-capacity cDNA reverse 
transcription kit (PE Applied Biosystems, CA, USA), and was then mixed with TaqMan 
Universal Master Mix (PE Applied Biosystems) and each TaqMan probe. Primer pairs 
and probes for various TAAs and β-actin were obtained from the TaqMan assay reagents 
library. Thermal cycling conditions were 25C for 10 min, 37C for 120 min, and 85C 
for 1 min. cDNA was subjected to quantitative real-time PCR analyses targeting various 
TAAs and β-actin. Analyses were performed using the StepOne Real-Time PCR system 
and StepOne v2.0 software. Relative gene expression values were determined. Data are 
presented as fold differences in TAA expression normalized to the housekeeping gene 
β-actin as an endogenous reference. 
 
Enzyme-linked immunospot assay (ELISPOT assay) 
Ninety-six-well plates (Millititer, Millipore, Bedford, MA) were coated with 
anti-human interferon-γ (IFN-γ) (Mabtech, Nacka, Sweden) at 4°C overnight and then 
washed 4 times with sterile PBS. The plates were then blocked with RPMI 1640 
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medium containing 5% FCS for 2 hr at room temperature. A total of 300,000 
unfractionated PBMCs were added in duplicate cultures of RPMI 1640 containing 5% 
FCS together with the peptides at 10 µg/ml. After 24 hr, the plates were washed 8 times 
with PBS and incubated overnight with 100 µl of the biotin-conjugated anti-human 
IFN-γ antibody. After another 4 washes with PBS, streptavidin-AP was added for 2 hr. 
Finally, the plates were washed again 4 times with PBS and developed with freshly 
prepared NBT/BCIP solution (Biorad, Hercules, CA). The reaction was stopped by 
washing with distilled water and drying at room temperature. Colored spots with fuzzy 
borders, which indicated the presence of IFN-γ-secreting cells, were counted. The 
number of specific spots was determined by subtracting the number of spots in the 
absence of the antigen. Responses were considered positive if 10 or more specific spots 
were detected and if the number of spots in the presence of an antigen was at least 
2-fold that in its absence. 
 
Peptide-specific CTL induction and cytotoxicity assay 
Synthetic peptide-specific T cells were expanded from PBMCs in 96-well 
round-bottom plates (NUNC, Naperville, IL). Four hundred thousand cells/well were 
stimulated with synthetic peptides at 10 µg/ml, 10 ng/ml rIL-7, and 100 pg/ml rIL-12 
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(Sigma) in RPMI 1640 supplemented with 10% heat-inactivated human AB serum, 100 
U/ml penicillin, and 100 µg/ml streptomycin. The cultures were restimulated with 10 
µg/ml peptide, 20 U/ml rIL-2 (Sigma), and 10
5
 mitomycin C-treated autologous PBMCs 
as feeder cells on days 7 and 14. One hundred microliters of RPMI medium with 10% 
human Ab serum and rIL-2 at a final concentration of 10 U/ml was added to each well 
on days 4, 11, and 18. The cytotoxicity assay was conducted on day 22. 
 The C1R-A24 and human pancreatic cancer cell lines were used as target cells 
for the 
51
Cr release assay. C1R-A24 cells were incubated overnight with 10 µg/ml 
synthetic peptides and labeled with 25 µCi of 
51
Cr for 1 hour. Pancreatic cancer cell 
lines were also labeled with 25 µCi of 
51
Cr for 1 hour without incubation with peptides. 
After three washes with PBS, target cells were plated at 3,000 cells/well in complete 
medium in round-bottom 96-well plates. Unlabeled K562 (120,000 cells/well) was 
added to reduce non-specific lysis. Peptide-stimulated PBMCs were added at various 
effector-to-target ratios as indicated. Maximum release was determined by the lysis of 
51
Cr-labeled targets with 5% Triton X-100 (Sigma Chemical). Spontaneous release was 
<10% of maximum release for all experiments, except for when it was <15% when the 
target cells were human pancreatic cancer cell lines. Percent-specific cytotoxicity was 
determined using the following formula: 100×(experimental release – spontaneous 
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release) / (maximum release – spontaneous release), and specific cytotoxic activity was 
calculated as follows: (cytotoxic activity in the presence of the peptide) – (cytotoxic 
activity in the absence of the peptide). Specific cytotoxicity of more than 10% was 
considered to be positive. 
 
Tetramer staining and flow cytometry 
TAA-specific tetramers were purchased from Medical Biological Laboratories 
Co., Ltd. (Nagoya, Japan). Tetramer staining was performed as described below. One 
million isolated PBMCs or peptide-specific CTLs pulsed with TAA-derived peptides 
were washed, resuspended in 200 µl of PBS without calcium or phosphate, and stained 
with 40 µg/ml tetrameric complexes and monoclonal antibodies against cell surface 
proteins for 30 min at room temperature. The following monoclonal antibodies were 
used: anti-CD8-APC (BD PharMingen, San Diego, CA), anti-CCR7-FITC, 
anti-CD45RA-PerCP, and tetramer-PE. Cells were washed, fixed with 0.5% 
paraformaldehyde/PBS, and analyzed on a Becton Dickinson FACSAria II system. 
 
Statistical analysis 
Fisher’s exact test and unpaired Student’s t-test were used to analyze the effect of 
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variables on immune responses in pancreatic cancer patients. Overall survival was 
calculated from the day of pancreatic cancer diagnosis until the date of death or the last 
day of the follow-up period. Cumulative survival proportions were calculated using the 
Kaplan-Meier method, and any differences were evaluated using the log-rank test. A 
p-value of less than 0.05 was considered to be significant, and all the tests were 
two-sided. All statistical analyses were performed using the SPSS statistical software 






Patient characteristics are summarized in the Supplementary Table. The median 
age of patients was 72 years, and patients included 24 males (59%). The main 
localization of the tumors was the pancreatic head in 39% of patients and the pancreatic 
body or tail in 61%. The majority of patients (93%) had advanced-stage cancer, namely, 
UICC stage III or IV. Therapeutic procedures mainly involved chemotherapy consisting 
of protocols such as gemcitabine monotherapy, S-1 monotherapy, or a combination of 
both drugs. Only 11 patients received the best supportive therapy to relieve physical and 
spiritual pain. A total of 61% of patients had died by the last day of the follow-up period 
and the median overall survival time of patients was 7.2 months. 
 
TAA expression in pancreatic cancer cell lines and human cancer tissues 
We evaluated the expression of 17 different TAAs in 9 human pancreatic cancer 
cell lines using real-time PCR. Although differences were observed from cell to cell, 
TAAs were expressed in more than 40% of pancreatic adenocarcinoma cell lines, except 
for adenocarcinoma antigens recognized by T cells (ART)1 (11%) and ART4 (33%) 
(Table 2). We then investigated TAA expression in 7 surgical and 5 autopsy specimens. 
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The expression of most TAAs in pancreatic adenocarcinoma specimens was similar to 
or more frequent than that in human pancreatic cancer cell lines, except for 
melanoma-associated antigen (MAGE)-A1 and MAGE-A3 (Table 2). 
 
Detection of TAA-specific T cells by IFN-γ ELISPOT analysis 
IFN-γ ELISPOT responses were evaluated with PBMCs to determine how 
frequently T cells respond to TAA-derived peptides and control peptides in patients with 
pancreatic adenocarcinoma (Figure 1A). Positive responses to at least one TAA-derived 
peptide were observed in 28 of 41 (68%) patients. On the other hand, 14 of 23 (61%) 
peptides were recognized by T cells obtained from at least one patient. ART1188, 
ART4161, ART4899, lymphocyte-specific protein tyrosine kinase (Lck)208, MAGE-A3195, 
p53161, human telomerase reverse transcriptase (hTERT)461, hTERT324, Wilms tumor 
(WT)-1235, vascular endothelial growth factor receptor (VEGFR)2169, and VEGFR11084 
were recognized in more than two patients, which suggested that these peptides have the 
potential to be immunogenic. Peptides 24 (HIVenv584) and 25 (CMVpp65328) were 
recognized in 0% and 38% of patients, respectively. 
Peptides ART4161, ART4899, Cyclophilin B (Cyp-B)315, Lck208, hTERT324, and 
VEGFR11084 were recognized in more than one healthy volunteer and/or the percentage 
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of positive responses was higher in healthy volunteers than in pancreatic 
adenocarcinoma patients, which indicated that the responses to these peptides were not 
specific to T cells from patients with pancreatic adenocarcinoma (Figure 1B). In other 
words, peptides ART1188, MAGE-A3195, p53161, hTERT461, WT-1235, and VEGFR2169 
have specific immunogenic potential in patients with pancreatic adenocarcinoma. 
The number of peptide-specific IFN-γ-producing T cells was counted to examine 
the frequency of T cells responsive to TAA-derived peptides. A range of 10 to 46 T cells 
per 300,000 PBMCs in patients with pancreatic adenocarcinoma produced IFN-γ 
(Figure 1C). 
 
TAA-specific CTL induction and cytotoxic activity 
We attempted to induce peptides specific to CTLs from the PBMCs of pancreatic 
adenocarcinoma patients. Cytotoxicity assays were performed in more than five patients 
for each peptide. Of the 11 peptides recognized in more than two patients in the IFN-γ 
ELISPOT assay, 6 peptides (MAGE-A3195, p53161, hTERT461, hTERT324, WT-1235, and 
VEGFR2169) could induce their specific CTLs, which were confirmed to be able to 
respond to C1RA24 cells pulsed with corresponding peptides by the cytotoxicity assay, 
as shown in Figure 2A. 
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We conducted a cytotoxicity assay to determine whether peptide-specific CTLs 
from healthy volunteers could show their cytotoxic activity against pancreatic 
carcinoma cell lines. P53161-, hTERT461-, and hTERT324-specific CTLs showed 
cytotoxicity against YPK-2 (HLA-A24-, p53-, and hTERT-positive), but not against 
Panc-1 (HLA-A24-negative, p53- and hTERT-positive). MAGE-A3195-, WT-1235-, and 
VEGFR2169-specific CTLs also showed cytotoxic activity against YPK-2 (HLA-A24-, 
MAGE-A3-, WT-1-, and VEGFR2-positive), but not against YPK-1 (HLA-A24 positive, 
MAGE-A3-, WT-1-, and VEGFR2-negative). Representative data are shown in Figure 
2B. 
 
Phenotypic analysis of TAA-derived peptides specific to T cells 
To analyze the characteristics of TAA-derived peptides specific to T cells and 
select the appropriate epitope for immunotherapy in patients with pancreatic 
adenocarcinoma, we performed phenotypic analysis by tetramer staining and FACS 
analysis. We first attempted to detect MAGE-A3195-, hTERT461-, and WT-1235-specific 
tetramer-positive T cells in PBMCs and CTLs induced by the corresponding peptides in 
healthy volunteers. The ratio of tetramer-positive T cells was increased in CTLs and 
their frequencies were 1.481-2.930% of CD8
+
 T cells, suggesting that these tetramers 
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work well (Figure 3A). We also conducted similar assays in pancreatic adenocarcinoma 
patients and detected tetramer-positive T cells in CTLs (Figure 3B). 
We then examined the naïve/effector/memory phenotype of tetramer-positive 
cells in the PBMCs of patients. The memory phenotype was investigated by the 
criterion of CD45RA/CCR7 expression [28]. In tetramer analysis, the frequencies of 
MAGE-A3195-, hTERT461-, and WT-1235-specific tetramer-positive T cells were 
0.003-0.044%, 0.006-0.053%, and 0.030-0.191% of CD8
+














(effector) T cells in tetramer-positive cells depended on the 
patient and all phenotypes were observed in all patients, except for patients 1, 8, 28, 29, 
and 4 (Supplementary Figure 1). 
 
TAA-specific T-cell responses and clinical features of pancreatic cancer patients 
In the present study, we analyzed the clinical features that can affect TAA-specific 
immune responses. When we divided patients into two groups based on their 
frequencies of lymphocyte subsets in peripheral leukocytes (less than 24%, the median 
value among all patients, or equal to or more than 24%) and the strength of 
TAA-specific immune responses into three groups according to the frequency of 
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TAA-specific T cells (less than 10 specific spots on ELISPOT assays, no response; 
10-19 specific spots, weak response; equal to or more than 20 specific spots, strong 
response), the patients with more lymphocyte subsets in peripheral leukocytes showed 
stronger TAA-specific T-cell responses (Supplementary Figure 2). On the other hand, 
we could not find any relationship between TAA-specific immune responses and other 
clinical characteristics such as age, sex, tumor marker levels, UICC stage, or metastasis 
status. 
We also analyzed the correlation between T-cell responses and the prognosis of 
pancreatic cancer patients. The median overall survival time of patients with T-cell 
responses to at least one TAA-derived peptide evaluated by the ELISPOT assay was 
12.2 months, which was significantly longer than that without T-cell responses (4.3 
months) (p =0.013) (Figure 4A). On the other hand, no correlation was observed 
between positive T-cell responses and CMV-derived peptides and clinical outcomes 
(Figure 4B), suggesting that TAA-specific T-cell responses, but not the general immune 
response, is a prognostic factor in patients with pancreatic adenocarcinoma. The 
frequencies of regulatory T cells or the ratio of regulatory T cells to CD8
+
 T cells had no 




Immunotherapy is considered to be a fourth treatment procedure for cancer 
following surgical resection, radiotherapy, and chemotherapy [29]. Cancer vaccine 
therapy was previously shown to convey survival benefits to prostate cancer patients in 
a clinical phase III trial [30], and some candidates of other cancers have been identified 
and separately evaluated to determine whether a CTL response can be elicited, with the 
subsequent elimination of cancer cells and improvement in outcomes. Although a 
successful clinical response depends on how much tumor antigens elicit their specific 
CTLs, which are the most important effector cells for antitumor immune responses, to 
the best of our knowledge, no studies have attempted to identify which epitopes are 
optimal for peptide vaccine therapy in patients with pancreatic adenocarcinoma. 
Therefore, we simultaneously compared peptide-specific T-cell responses among 
various TAAs in 41 identical patients with pancreatic adenocarcinoma under the same 
experimental conditions. 
Therapeutic function is the most important factor to consider when determining 
the usefulness of cancer antigens for peptide vaccine therapy. However, it is very 
difficult to compare the efficacy of more than one epitope, especially in patients with 
pancreatic adenocarcinoma whose survival time is very short. Under such circumstances, 
immunogenicity, specificity, oncogenicity, expression levels, % positive cells, and the 
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number of patients with antigen-positive cancer are considered to be alternative criteria 
[31]. On the basis of our results, p53161, hTERT461, WT-1235, and VEGFR2169 are 
considered the most optimal epitopes that satisfy all of the above criteria for peptide 
vaccine therapy in pancreatic adenocarcinoma patients. Although MAGE-A3195 showed 
immunogenicity, its expression did not appear to be high in pancreatic adenocarcinoma 
tissue [32]. Therefore, it may be a candidate for cancer vaccine therapy when 
MAGE-A3 is confirmed to be overexpressed in pancreatic cancer tissue. 
A mutation in the p53 gene and overexpression of the p53 protein have been 
reported previously in pancreatic adenocarcinoma [33], and all pancreatic cancer cell 
lines and specimens used in our study expressed p53. Some strategies targeting p53 
have been proposed over the last decade [34]. As peptide vaccine therapy, the wild-type 
p53 peptide is well preserved in mutant p53 because most mutations in the p53 gene are 
missense mutations, and are considered to be one of the attractive targets as a cancer 
antigen. The frequencies of the CTL response against HLA-A24-restricted p53161 
investigated by the ELISPOT assay in head and neck carcinoma and hepatocellular 
carcinoma were shown to be 35% and 10%, respectively [35,36]. Although the 
frequency of 7% in our study is lower, given the difference according to the primary 
tumor site or balance between sensitivity and specificity, induced CTLs showed 
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cytotoxic activity against pancreatic adenocarcinoma cell lines, which suggested that 
p53 may be an attractive target in patients with pancreatic cancer. 
hTERT is widely overexpressed in various cancer cells including pancreatic 
cancer [37], which is consistent with our results. A clinical trial demonstrated that 
GV1001, a HLA class II epitope corresponding to the hTERT (611-626) fragment, was 
immunogenic in pancreatic cancer patients [38]. Another previous study evaluating 
T-cell responses to several hTERT epitopes in patients with hepatocellular carcinoma 
[39] demonstrated that hTERT461- and hTERT324-specific CTLs were induced in 5 
(6.9%) and 9 (12.5%) of 72 patients, respectively. In the current study, these frequencies 
were equivalent and the killing of pancreatic cancer cell lines was demonstrated, which 
suggested that these epitopes also had immunogenicity in pancreatic cancer patients. 
Peptide vaccine therapies using WT-1235 and VEGFR2169 combined with 
gemcitabine have already been conducted in pancreatic adenocarcinoma patients [23,24]. 
We clarified that WT-1235- and VEGFR2169-specific CTLs induced from PBMCs 
showed cytotoxicity for human pancreatic cancer cell lines, and the results of further 
investigations are anticipated. 
We performed phenotypic analysis of TAA-derived epitope-specific T cells to 





 cells in PBMCs were also found in patients 
without IFN-γ ELISPOT responses, which was consistent with the findings of previous 
studies [39,40] and suggested the existence of dysfunctional epitope-specific T cells. 
Epitope-specific tetramer
+
 cells were also identified at a very low frequency in PBMCs 
from healthy volunteers and increased in CTLs induced with TAA-derived peptides, 
which was also consistent with previous studies in which TAA-specific tetramer
+
 T cells 
were detectable in samples from healthy donors [41] or the in vitro stimulation of 
PBMCs with the epitopes derived from TAA could induce TAA-specific CTLs in 
healthy volunteers [42], even though the precise mechanism has not yet been clarified. 
Phenotypic analysis showed that the frequency of T cells with each memory and 
effector phenotype depended on the patient and also that peptide-specific memory T 
cells existed in PBMCs of patients with pancreatic adenocarcinoma. Because T cells 
with the memory phenotype exert stronger antitumor effects by secondary stimulation 
with the antigen, our results suggest that an additional immunological approach such as 
that consisting of a TAA-derived protein or peptide, recombinant virus, and engineered 
tumor cells to boost T-cell function may be useful to enhance host antitumor immune 
responses. 
Another purpose of this study was to identify the factors influencing immune 
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responses. Our results suggested that the frequencies of the lymphocyte subsets in 
peripheral leukocytes were very important in the induction of TAA-specific CTLs. 
Although the relationship between cancer, inflammation, and immunity has already 
been documented [43], the precise mechanism has yet to be fully understood. One of the 
speculated reasons why PBMC from patients with lymphocytopenia could not induce a 
good immune response in our study is that the release of inhibitory immunological 
cytokines such as transforming growth factor β or IL-10 from pancreatic 
adenocarcinoma tissue decreases lymphocyte counts and impairs the function of 
lymphocytes both systemically and in the microenvironment [44]. It was also reported 
that lymphocyte counts and CTL responses were prognostic markers in advanced cancer 
cases receiving peptide vaccine therapy [45, 46]. Our results showing a correlation 
between the T-cell response and outcomes in pancreatic adenocarcinoma patients 
corresponded to these previous findings, which indicates that restricting the objective to 
those with an adequate lymphocyte subset could lead to a clinical trial with favorable 
outcomes. 
A limitation of this study was the lack of data for the clinical response. Tumor 
shrinkage or survival benefits are not always observed in all patients who exhibit 
immune responses. Further clinical studies using peptides that could induce 
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TAA-specific CTLs are needed to confirm our findings. 
In conclusion, we simultaneously compared T-cell responses to various 
TAA-derived epitopes in patients with pancreatic adenocarcinomas; our results 
suggested that p53161, hTERT461, WT-1235, and VEGFR2169 were the most suitable 
epitopes for cancer vaccine therapy. 
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Figure 1: T-cell responses to TAA-derived peptides and control peptides in pancreatic 
adenocarcinoma patients A) and healthy volunteers B). T-cell responses were evaluated 
by the IFN-γ ELISPOT assay. Responses were considered positive if 10 or more 
specific spots were detected and if the number of spots in the presence of an antigen was 
at least 2-fold that in its absence. Black boxes indicate positive responses. C) The 
frequency of TAA-specific IFN-γ-producing T cells evaluated by the ELISPOT assay. 
Black bars indicate the response of one patient. 
 
Figure 2: A) T-cell responses to peptides evaluated by the cytotoxicity assay. 
Peptide-specific CTL induction and cytotoxicity assays were performed on the PBMCs 
from at least five patients and representative data are shown when peptide-specific 
CTLs were induced in one or more patients. A percent-specific cytotoxicity of more 
than 10% was considered to be positive. Six peptides: 9, 14, 18, 19, 20, and 21, could 
induce their specific CTLs, and these could respond to C1RA24 cells pulsed with the 
corresponding peptides in the cytotoxicity assay. B) Cytotoxic activity against the 
pancreatic carcinoma cell lines of TAA-specific CTLs from healthy volunteers 
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evaluated by the cytotoxicity assay. Cytotoxicity was stronger against pancreatic 
carcinoma cells that were HLA-A24-restricted and expressed corresponding TAAs than 
against those not HLA-A24-restricted or not expressing corresponding TAAs. 
 




 lymphocytes in 
PBMCs from healthy volunteers and pancreatic adenocarcinoma patients. A) Tetramer 
analyses were performed on eight healthy volunteers for each peptide (MAGE-A3195, 




 T cells were detectable in both PBMCs 
and CTLs induced by their corresponding peptides in at least one healthy volunteer, and 
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 T cells was higher in CTLs induced with each TAA-derived peptide than in 
PBMCs. B) Tetramer analyses were performed on pancreatic adenocarcinoma patients 
using PBMCs and CTLs which was induced with TAA-derived peptides and showed 
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Figure 4: Kaplan-Meier plot of the overall survival of pancreatic cancer patients 
according to A) TAA-specific T-cell responses and B) T-cell responses to CMV-derived 
peptides. A) TAA-specific T-cell responses were defined as positive if 10 or more 
specific spots to at least one TAA-derived peptide were detected on the ELISPOT assay. 
The overall survival time of patients with TAA-specific T-cell responses was 
significantly longer than that of patients without TAA-specific T-cell responses. B) 
T-cell responses to CMV-derived peptides were defined as positive if 10 or more 
specific spots to CMV-derived peptides were detected on ELISPOT assays. No 
correlation was observed between positive T-cell responses to CMV-derived peptides 
and the clinical outcomes of patients.  
 
